These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11363523)

  • 1. New "ThetaSwitch" drug may increase long-term survival in HIV disease.
    J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):59. PubMed ID: 11363523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic inhibition of AZT-resistant HIV by AZT combined with poly(I):poly(C12U), without synergistic toxicity to bone marrow progenitor cell elements.
    Gillespie D; Hubbell HR; Carter WA; Midgette P; Elsasser W; Mullaney R; Strayer DR
    In Vivo; 1994; 8(3):375-81. PubMed ID: 7803722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial will add immunotherapeutic agent to first cycle of antiviral cocktails.
    AIDS Read; 2001 Feb; 11(2):85. PubMed ID: 11279885
    [No Abstract]   [Full Text] [Related]  

  • 4. An hypothesis concerning optimal therapy in HIV disease.
    Gillespie D; Carter WA
    Med Hypotheses; 1992 Jan; 37(1):1-5. PubMed ID: 1569900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection.
    Thompson KA; Strayer DR; Salvato PD; Thompson CE; Klimas N; Molavi A; Hamill AK; Zheng Z; Ventura D; Carter WA
    Eur J Clin Microbiol Infect Dis; 1996 Jul; 15(7):580-7. PubMed ID: 8874076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute reactions associated with the infusion of ampligen.
    McMahon D; Winkelstein A; Huang XL; Armstrong J; Pazin G; Rinaldo C; Tripoli C; Ho M
    AIDS; 1992 Feb; 6(2):235-6. PubMed ID: 1558725
    [No Abstract]   [Full Text] [Related]  

  • 8. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer.
    Jasani B; Navabi H; Adams M
    Vaccine; 2009 May; 27(25-26):3401-4. PubMed ID: 19200817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3TC: combination trial stopped early as clinical benefit shown.
    James JS
    AIDS Treat News; 1996 Aug; (no 252):5. PubMed ID: 11363752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anti-HIV-1 therapies and combinations: current data and prospects.
    Eron JJ; Hirsch MS
    AIDS; 1990; 4 Suppl 1():S193-200. PubMed ID: 2152567
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV infection and zidovudine use in childbearing women.
    Sia J; Paul S; Martin RM; Cross H
    Pediatrics; 2004 Dec; 114(6):e707-12. PubMed ID: 15545619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ampligen trials.
    Am Fam Physician; 1990 Oct; 42(4):1123. PubMed ID: 2088344
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-HIV therapy lowers risk of AIDS, death in patients with intermediate-stage HIV disease.
    AIDS Patient Care; 1995 Dec; 9(6):303. PubMed ID: 11361440
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase I study of ampligen in human immunodeficiency virus-infected subjects.
    Armstrong JA; McMahon D; Huang XL; Pazin GJ; Gupta P; Rinaldo CR; Schoenfeld DA; Gaccione P; Tripoli CA; Bensasi S
    J Infect Dis; 1992 Oct; 166(4):717-22. PubMed ID: 1527407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of HIV: the cutting edge of clinical trial design.
    Crit Path AIDS Proj; 1996; (No 31):16-7. PubMed ID: 11363825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Zidovudine therapy alone is not enough].
    Fortschr Med; 1995 Nov; 113(32):13-4. PubMed ID: 8543268
    [No Abstract]   [Full Text] [Related]  

  • 18. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M;
    Antivir Ther; 2001 Jun; 6(2):127-34. PubMed ID: 11491417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beating HIV at its own game: the success of IL-2.
    Rochon D
    Res Initiat Treat Action; 1998 Dec; 4(7):15-6. PubMed ID: 11366082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease.
    Carter WA; Ventura D; Shapiro DE; Strayer DR; Gillespie DH; Hubbell HR
    Int J Immunopharmacol; 1991; 13 Suppl 1():69-76. PubMed ID: 1688087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.